This review critically evaluates recent technological advances, therapeutic applications, and translational progress of microneedle (MN)-assisted delivery systems for biologics, with an emphasis on insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, monoclonal antibodies, and cancer vaccines
Individuals with T1D were eligible if they met the following criteria: (1) on insulin therapy, (2) no prior use of GLP-1RA, (3) available measurements of body mass index (BMI) and HbA1c measurements at T0 and (4) at least 12 months of engagement with the health system before T0
GLP-1 (glucagon-like peptide-1) helps regulate blood sugar, reduce appetite, and increase feelings of fullness, making it easier for patients to manage their weight
Light Sensitivity: GLP-1 research peptides should be kept in amber vials or stored in total darkness to prevent photo-oxidation of sensitive amino acids like tryptophan or tyrosine
Restarting with a new medication can trigger setbacks, new side effects, and reduced effectiveness